LYB001

Last updated

LYB001
Vaccine description
Target SARS-CoV-2
Vaccine type Virus-like particles
Clinical data
Routes of
administration 		Intramuscular

LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd. [1] [2] [3] [4]

It was found to be safe and well tolerated. [5]

References

  1. ↑ "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
  2. ↑ "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov . 18 November 2021. NCT05125926. Retrieved 18 November 2021.
  3. ↑ "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
  4. ↑ "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov . 30 November 2021. NCT05137444. Retrieved 30 November 2021.
  5. ↑ Tang R, Zeng Y, Zhou Y, Liang Q, Kang W, Yang Z, et al. (2 May 2024). "Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study". Expert Review of Vaccines. 23 (1): 498–509. doi: 10.1080/14760584.2024.2337051 . PMID   38695310.
Syringe with Green Fluid.jpg

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.